Skip to main content
All Posts By

laurabbook@gmail.com

Future Medicine
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer ResearchTreatments

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer

*March 2022* Lung cancer is one of the most common malignant cancers worldwide. Specific genes are known to drive cancer growth in advanced non-small-cell lung cancer (NSCLC) and targeted therapies against these genes and their proteins have significantly improved survival. However, resistance to these therapies inevitably occurs and there is…
laurabbook@gmail.com
July 3, 2022
frontiers in oncology logo
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report ResearchTreatments

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

*April 2022* Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. Methods: Patients were identified from a prospective database developed by Boehringer Ingelheim and via literature review. Mutations were…
laurabbook@gmail.com
July 3, 2022
Nature Magazine
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management ResearchTreatments

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

*May 2022* Key Points NSCLCs harboring oncogenic EGFR mutations or ALK rearrangements can be effectively treated with EGFR and ALK TKIs respectively. The third-generation TKI osimertinib and the ALK TKI lorlatinib are currently the most advanced and effective clinically approved agents in their respective NSCLC subsets; both agents are highly…
laurabbook@gmail.com
July 3, 2022
ASCO Educational Book logo
Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It? Coping With Cancer

Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?

*May 2022* Patients with cancer face a trajectory marked by emotional and physical distress that can be associated with both diagnosis and treatment. Fear of cancer recurrence or progression has been considered one of the most common unmet needs reported by patients diagnosed with both localized and metastatic disease. Fear…
laurabbook@gmail.com
July 3, 2022
FDA Food and Drug Admin Logo
FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics Advocacy

FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics

*May 2022* EGFR Resisters co-founder Jill Feldman participated as a panelist in this FDA Oncology Workship:  3a "Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics; and 3b "Opportunities to Improve Dose Optimization: Assessing Safety and Tolerability." Current strategies for determining the recommended dose(s) of anticancer agents for evaluation…
laurabbook@gmail.com
July 3, 2022
EGFR Resister Logo
Drs. Christine Lovly and Helena Yu discuss and answer questions about their research projects funded by the EGFR Resisters ResearchTreatments

Drs. Christine Lovly and Helena Yu discuss and answer questions about their research projects funded by the EGFR Resisters

*May 2022* Dr. Upal Basu Roy from the LUNGevity Foundation conducts discussions with Drs. Christine Lovly and Helena Yu, along with EGFR Resisters co-founders Ivy Elkins and Jill Feldman. Both Lovely and Yu received research awards from the EGFR Resisters and provide updates on their projects in this video. Dr.…
laurabbook@gmail.com
July 3, 2022
Targeted Oncology
EGFR Tyrosine Kinase Inhibitors and SCLC Transformation ResearchTreatments

EGFR Tyrosine Kinase Inhibitors and SCLC Transformation

*April 2022* Ravi Salgia, MD, medical oncologist, professor, and chair, Department of Medical Oncology & Therapeutics Research, and Arthur & Rosalie Kaplan chair in Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell…
laurabbook@gmail.com
July 3, 2022